Ten stocks kicked off the first trading day of the month, clocking in double-digit gains, thanks to a flurry of positive developments, including billion-dollar partnerships and buy recommendations from the most trusted investment companies, among other catalysts.

In this article, we have listed down the names of the top-performing stocks on Monday that significantly outperformed Wall Street’s major indices, so you can decide whether it is now time to book profits or double down on your investments.

To come up with the list, we only focused on the mid-cap stocks—companies with a $2 billion market capitalization and 5 million daily trading volume.

10. Nucor Corp. (NYSE:NUE)

Nucor Corp. rallied by 10.10 percent on Monday to close at $120.40 apiece as investors snapped up shares following President Donald Trump’s slapping of a 50-percent tariff on all steel and aluminum imports.

On Friday, Trump said the new levies will take effect tomorrow, June 4, hours after accusing China of violating an agreement with the US to mutually reduce levies and trade restrictions for critical minerals.

The US Midwest duty-paid aluminum premium AUPc1 surged by 54 percent or $0.58 per lb to $1,279 per metric ton on Monday, while US hot rolled coil steel increased by 7.4 percent.

Following the news, BMO Capital Markets raised its price target for Nucor Corp. (NYSE:NUE) to $145 from $140 previously and assigned the company an “outperform” rating, an upgrade from the “market perform” prior.

Nucor Corp. (NYSE:NUE) is one of the largest steel companies in the US, and currently the 16th largest producer in the world.

9. First Majestic Silver Corp. (NYSE:AG)

First Majestic Silver grew its share prices by 11.51 percent on Monday to finish at $6.88 apiece as investors turned bullish on the company following its discovery of a new gold-silver deposit that could significantly raise its future production.

Last week, First Majestic Silver Corp. (NYSE:AG) announced the discovery of a new gold-silver deposit called Sto. Nino, one kilometer away from the Santa Elena mining property in Sonora, Mexico.

Additionally, it was able to raise the production of its Navidad deposit at the same site following the success of its drilling operations.

First Majestic Silver Corp. (NYSE:AG) said that the addition of Navidad and Sto. Nino raised the number of its hosted production sites to four, the others being Sta. Elena and Ermitano.

“The Santo Niño discovery marks yet another exciting milestone for the district, and the drilling shows the vein remains open for expansion in most directions. At the same time, step-out drilling at the Navidad Discovery continues to intercept exceptionally high-grade mineralization and expand the resource envelope,” said First Majestic Silver Corp. (NYSE:AG) President and CEO Keith Neumeyer.

8. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals surged by 13.05 percent on Monday to finish at $19.14 apiece after earning a higher price target from an investment firm.

On Monday, Wells Fargo raised its price target for the company to $29 from $26 previously, while maintaining an “equal weight” rating for the stock.

Wells Fargo said that the adjustment reflected its optimism about Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) potential treatment for rare kidney diseases C3G and IC-MPGN, which could bolster opportunities for the company.

Wells Fargo expected the treatment to secure an approval, but underscored the need for a clearer understanding of its potential downside risks before becoming more optimistic on the stock.

In the first quarter of the year, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) widened its net loss by 39 percent to $92 million from $66 million in the same period last year. Revenues inched up by 3 percent to $166.8 million from $172.3 million year-on-year.

7. Tempus AI, Inc. (NASDAQ:TEM)

Tempus AI extended its winning streak to a third consecutive day on Monday, jumping 15.02 percent to close at $63.47 apiece as investors snapped up shares after earning a “buy” recommendation despite being hit by a negative short-seller report.

On Monday, TD Cowen maintained its “buy” recommendation on Tempus AI, Inc.’s (NASDAQ:TEM), pricing it at $62, albeit lower than its latest closing price.

The recommendation followed Spruce Point Capital’s report on the company, saying it sees a “50 to 60 percent potential long-term downside and market underperformance risk.”

“We believe the Tempus equity growth story is built on hype and appeal to retail investors that it is an exciting and disruptive technology play with AI appeal, which could have the next Tesla or Nvidia-type inflection,” Spruce Point was quoted as saying.

For its part, Tempus AI, Inc. (NASDAQ:TEM) said that it would not respond to a report “riddled with hypotheticals and inaccuracies.”

“We remain focused on delivering shareholder value, taking advantage of the enormous opportunity of bringing AI to healthcare, and helping patients live longer and healthier lives,” it said.

6. BioNTech SE (NASDAQ:BNTX)

BioNTech saw its share prices grow by 18.05 percent on Monday to finish at $113.10 apiece following news that it joined forces with Bristol Myers Squibb for the development of a next-generation cancer immunotherapy for $11.1 billion.

In a statement, BioNTech SE (NASDAQ:BNTX) said it partnered with Bristol Myers to broaden and accelerate the development of BNT327 across numerous solid tumor types.

Bristol Myers will pay BioNTech SE (NASDAQ:BNTX) $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028.

Additionally, BioNTech SE (NASDAQ:BNTX) will be eligible to receive up to $7.6 billion in additional development, regulatory, and commercial milestones.

The two companies will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions, and equally share global profits or losses.

5. Cleveland-Cliffs Inc. (NYSE:CLF)

Cleveland-Cliffs snapped a two-day losing streak on Monday, surging 23.16 percent to end at $7.18 apiece as investors flocked to US steelmakers following President Donald Trump’s new tariff bomb.

On Friday, Trump said that he would impose a 50-percent tax on steel and aluminum imports effective tomorrow, June 4.

The new levies followed his accusation against China of violating an agreement with the US to mutually reduce levies and trade restrictions for critical minerals.

The US Midwest duty-paid aluminum premium AUPc1 surged by 54 percent or $0.58 per lb to $1,279 per metric ton on Monday, while US hot rolled coil steel increased by 7.4 percent.

The imposition of new duties on imported steel and aluminum products makes domestic manufacturers such as Cleveland-Cliffs Inc. (NYSE:CLF) more appealing to investors as it may bolster demand for their products, support competitive pricing for locally-produced goods, and further reduce competition with international producers.

Cleveland-Cliffs Inc. (NYSE:CLF) is a US-based steel and iron ore manufacturer based in Cleveland, Ohio.

4. Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion.

Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion.

In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.

The upfront offer price represents a 27-percent premium over Blueprint’s closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025.

The purchase will also include the latter’s rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM).

3. Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Kymera Therapeutics saw its share prices surge by 45.51 percent on Monday to end at $43.13 apiece following the early-stage success of its drug candidate for the treatment of the moderate to severe form of eczema.

In a statement, Kymera Therapeutics, Inc. (NASDAQ:KYMR) said that its primary objective to demonstrate that its drug candidate, KT-621, could achieve robust STAT6 degradation in blood and skin went “well beyond our expectations.”

The first phase of the trial enrolled 118 healthy volunteers who tested the safety and tolerability of KT-621.

“Building from the compelling preclinical data … is a powerful demonstration of what we believe is an impeccable translation into humans,” it said.

If the drug succeeds all trials and secures regulatory approvals, it would rival Sanofi and Regeneron’s blockbuster therapy, Dupixent.

Following the trial results, Kymera Therapeutics, Inc. (NASDAQ:KYMR) earned a “buy” recommendation and a higher price target of $51 from Bank of America, versus $44 previously.

2. Applied Digital Corporation (NASDAQ:APLD)

Applied Digital saw its share prices increase by 48.46 percent on Monday to close at $10.14 apiece after clinching a $7-billion deal with CoreWeave.

In a statement, Applied Digital Corporation (NASDAQ:APLD) said that it entered into two 15-year lease agreements with CoreWeave, under which the former will deliver 250 megawatts of critical IT load to host CoreWeave’s artificial intelligence (AI) and high-performance computing (HPC) infrastructure at its Ellendale, North Dakota data center campus.

Pursuant to the lease contracts, CoreWeave also retains the option to access an additional 150 MW of critical IT load at Ellendale, positioning the campus as a scalable hub for expanding AI and HPC workloads.

Applied Digital Corporation (NASDAQ:APLD) designed Ellendale for the speed and efficiency of deployment, prime location, AI-innovative design, and access to abundant, low-cost energy. It expects to deliver the first 100 MW of data center in the fourth quarter of the year, while the remaining 150 MW is expected to come online in the middle of 2026.

1. Vera Therapeutics, Inc. (NASDAQ:VERA)

Vera Therapeutics jumped by 67.49 percent on Monday to close at $31.74 apiece following the success of its pivotal ORIGIN Phase 3 trial for Atacicept—a novel therapy for Berger’s disease, also known as immunoglobulin A nephropathy (IgAN).

In a statement, Vera Therapeutics, Inc. (NASDAQ:VERA) said that it achieved its primary endpoint of reduction in proteinuria (UPCR) during the trial, having decreased by 46 percent from baseline and by 42 percent compared with placebo at week 36.

Other pre-specified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial

Additionally, Vera Therapeutics, Inc. (NASDAQ:VERA) reported a favorable safety profile for the treatment.

According to the company, it plans to meet with the Food and Drug Administration (FDA) to discuss the results and the regulatory pathway, and submit a Biologics License Application (BLA) in the fourth quarter of 2025.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.